19th IDS Congress
Paris 2023
23-27 May. 2023
The Immunology of Diabetes Society (IDS) is a scientific society dedicated to improving understanding and treatment of type 1 diabetes. IDS organizes a Congress every 18 months in major centres in Europe, North America and Asia/Oceania at which there are scientific presentations to further this goal.
Centre international de Conférences Sorbonne Université
4 place Jussieu - 44-55
75005 - Paris, France
*To submit before 15th February 2023
Confirmed Speakers
(by alphabetical order)
Peter Achenbach, Coralie Alabert, Mark Atkinson, Jean-François Bach, Burkhard Becher, Polly Bingley, Ezio Bonifacio, Marcela Brissova, Todd Brusko, Yi-Chun Chen, Jenny Couper, Mark M. Davis, Colin Dayan, Gerard Eberl, Decio L. Eizirik, Donna Farber, Carla Greenbaum, John Harris, Len Harrison, Matthias Hebrok, Kevan Herold, Heikki Hyoty, Eddie James, Matthew Johnson, Sally Kent, David Klatzmann, Jeffrey Krischer, Vito Lampasona, Peter E. Lipsky, Chantal Mathieu, Eoin McKinney, Cristina Nostro, Timo Otonkoski, Alberto Pugliese, Frédéric Rieux-Laucat, Bart Roep, Miguel Sanjuan, Pere Santamaria, Andrea Schietinger, Anath Shalev, Jeannette Soderberg, Tommi Suvitaival, Qizhi Tang, Timothy Tree, Taylor Triolo, Tommi Vatanen, Joseph Vieth, Carola Vinuesa, John Wentworth, Benjamin Youngblood, Tong Yue, Anette Ziegler
Wednesday 24th
8.20 am
11.00 am
Plenary 2: Eisenbarth Award Lecture – presented by M. Rewers
Len Harrison (Walter & Eliza Hall Institute, Melbourne)
9.00 am
Short Symposium 2: Immune and pancreas heterogeneity
Short Symposium 2: Immune and pancreas heterogeneity
Talk 7: Immune heterogeneity – HANDEL-I: Todd Brusko (University of Florida, Gainesville)
Talk 8: Pancreas heterogeneity – HANDEL-P: Marcela Brissova (Vanderbilt University, Nashville)
Oral Abstract 4
Oral Abstract 5
Oral Abstract 6
Long Symposium 2: Innovative interventions and preclinical development
Talk 9: Verapamil: Anath Shalev (University of Alabama, Birmingham)
Talk 10: HLA Class II nanoparticles: P. Santamaria (Parvus Therapeutics)
Talk 11: CAR Treg therapies: Qizhi Tang (UCSF)
Oral Abstract 7
Oral Abstract 8
Oral Abstract 9
10.30 - 11 am
Break
Parallel session : Improving the design of clinical trials in T1D: analysis of data from the Trial Outcome Markers Initiative (TOMI) collaboration - Room 109, barre 44-54, 1st floor.
The Trial Outcome Marker Initiative (TOMI) brings together data from >10,000 individuals with new-onset T1D including 2,900 from 21 different clinical trials. Analysis of C-peptide, HbA1c and composite outcomes will be discussed, which has provided significant insights into designing clinical trials for stage 3 T1D
12.00 pm
1.00 pm
1.00 - 2.00 pm
Lunch
2.00 pm
4.30 pm
Long Symposium 3: iPS-derived beta cells, present and future
Talk 12: Disease modeling using iPS islets: Timo Otonkoski (University of Helsinki)
Talk 13: Regeneration vs carcinogenesis: Maria Cristina Nostro (McEwen Stem Cell Institute, Toronto)
Talk 14: Creating stealthy beta cells: Matthias Hebrok (UCSF, San Francisco)
Oral Abstract 10
Oral Abstract 11
Oral Abstract 12
Debate 1: Infectious triggers in T1D: myth or reality?
Myth: Bart Roep (LUMC, Leiden)
Reality: Heikki Hyoty (University of Tampere)
5.30 pm
Poster Blast 2 (16 to 30)
90” and 1 plain slide/each
6.00 pm
2.00 - 3.30 pm
Poster Session 2 (16 to 30)
// Parallel session - Room 109
Improving the design of clinical trials in T1D: analysis of data from the Trial Outcome Markers Initiative (TOMI) collaboration
The Trial Outcome Marker Initiative (TOMI) brings together data from >10,000 individuals with new-onset T1D including 2,900 from 21 different trials. Analysis of metabolic and composite outcomes and their implications for designing trials for stage 3 T1D will be discussed